OssDsign to Collect Data on Catalyst Bone Graft

OssDsign received review board approval to establish PROPEL, a multi-center prospective spinal fusion registry, to study real-world data from patients who have been treated with OssDsign Catalyst.

OssDsign Catalyst received FDA clearance in 2020 and was launched in the U.S. in 2021. During 2022, clinics will gradually be enrolled to the...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0